TRDA · Entrada Therapeutics, Inc.
$6.05
-0.10 (-1.63%)
At close · Jul 23
Market Cap
$234.86M
Shares
38.82M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$25.42M
-87.9%
FY2025
Net Income
-$143.75M
-319%
FY2025
Operating Margin
-621.13%
-643.4pp
FY2025
Diluted EPS
-$3.47
-306.5%
FY2025
Operating Cash Flow
-$128.51M
-209.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $5.74M | $25.42M | $210.78M | $129.01M | — | — | — | |
| $143.25M | $142.27M | $125.31M | $99.88M | $66.61M | $35.93M | $21.1M | |
| $40.9M | $41.05M | $38.47M | $32.29M | $30.64M | $15.2M | $5.57M | |
| $184.15M | $183.32M | $163.77M | $132.18M | $97.25M | $51.13M | $26.67M | |
| -$178.41M | -$157.9M | $47.01M | -$3.16M | -$97.25M | -$51.13M | -$26.67M | |
| — | -621.13% | 22.3% | -2.45% | — | — | — | |
| $13.26M | $15.07M | $19.47M | $15.22M | $2.63M | -$31K | $144K | |
| $962K | $924K | $859K | $18.74M | $0 | $0 | $0 | |
| -$166.12M | -$143.75M | $65.63M | -$6.69M | -$94.62M | -$51.16M | -$26.52M | |
| — | -565.48% | 31.13% | -5.18% | — | — | — | |
| -$166.31M | -$143.06M | $65.39M | -$4.43M | -$96.67M | -$51.16M | — | |
| USD/shares | — | -$3.47 | $1.76 | -$0.20 | -$3.02 | -$8.16 | -$24.00 |
| USD/shares | — | -$3.47 | $1.68 | -$0.20 | -$3.02 | -$8.16 | -$24.00 |
| shares | — | 41.37M | 37.31M | 33.05M | 31.29M | 6.27M | 1.11M |
| shares | — | 41.37M | 39M | 33.05M | 31.29M | 6.27M | 1.11M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.40×
EV/EBIT
—
Biotechnology median 26.67×
P/E (TTM)
—
Biotechnology median 7.02×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $25,421,000 | $210,782,000 | $129,013,000 |
Key facts
CIK
1689375
CUSIP
29384C108
13F (30d)
14 filings
14 filers
Visit website
Investor relations